Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families
1997

Screening for TP53 mutations in Swedish breast cancer families

Sample size: 128 publication Evidence: moderate

Author Information

Author(s): M Zelada-Hedman, A-L B0rresen-Dale, A Clarol, J Chen, L Skoog, A Lindblom

Primary Institution: Karolinska Hospital, Stockholm, Sweden; Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway

Hypothesis

What is the prevalence of TP53 mutations in familial breast cancer?

Conclusion

No germline mutations were found in the patients, but mutations were detected in 14% of the tumor DNA samples.

Supporting Evidence

  • No germline mutations were found in any of the patients.
  • Mutations were found in 14% of the tumor DNA samples.
  • The frequency of somatic mutations in familial tumors is similar to sporadic breast tumors.
  • Previous studies suggested that TP53 mutations are involved in approximately 1% of familial breast cancer cases.

Takeaway

The study looked for changes in a gene called TP53 in families with breast cancer and found that while the gene didn't have changes in the patients, some tumors did have changes.

Methodology

Constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations in 128 patients from 109 families.

Limitations

The study confirms the low frequency of germline mutations in p53, suggesting limited clinical benefit in screening for these mutations in breast cancer families.

Participant Demographics

Patients were from 109 families with a history of familial breast cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication